GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Oramed Pharmaceuticals Inc (XTAE:ORMP) » Definitions » Cyclically Adjusted PB Ratio

Oramed Pharmaceuticals (XTAE:ORMP) Cyclically Adjusted PB Ratio : 0.86 (As of May. 26, 2024)


View and export this data going back to 2017. Start your Free Trial

What is Oramed Pharmaceuticals Cyclically Adjusted PB Ratio?

As of today (2024-05-26), Oramed Pharmaceuticals's current share price is ₪8.457. Oramed Pharmaceuticals's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2024 was ₪9.83. Oramed Pharmaceuticals's Cyclically Adjusted PB Ratio for today is 0.86.

The historical rank and industry rank for Oramed Pharmaceuticals's Cyclically Adjusted PB Ratio or its related term are showing as below:

XTAE:ORMP' s Cyclically Adjusted PB Ratio Range Over the Past 10 Years
Min: 0.7   Med: 3.78   Max: 16.95
Current: 0.87

During the past years, Oramed Pharmaceuticals's highest Cyclically Adjusted PB Ratio was 16.95. The lowest was 0.70. And the median was 3.78.

XTAE:ORMP's Cyclically Adjusted PB Ratio is ranked better than
66.31% of 653 companies
in the Biotechnology industry
Industry Median: 1.73 vs XTAE:ORMP: 0.87

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Oramed Pharmaceuticals's adjusted book value per share data for the three months ended in Mar. 2024 was ₪15.046. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is ₪9.83 for the trailing ten years ended in Mar. 2024.

Shiller PE for Stocks: The True Measure of Stock Valuation


Oramed Pharmaceuticals Cyclically Adjusted PB Ratio Historical Data

The historical data trend for Oramed Pharmaceuticals's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Oramed Pharmaceuticals Cyclically Adjusted PB Ratio Chart

Oramed Pharmaceuticals Annual Data
Trend Aug14 Aug15 Aug16 Aug17 Aug18 Aug19 Aug20 Aug21 Dec22 Dec23
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2.42 2.39 11.67 5.32 0.88

Oramed Pharmaceuticals Quarterly Data
May19 Aug19 Nov19 Feb20 May20 Aug20 Nov20 Feb21 May21 Aug21 Nov21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.92 1.45 1.02 0.88 1.09

Competitive Comparison of Oramed Pharmaceuticals's Cyclically Adjusted PB Ratio

For the Biotechnology subindustry, Oramed Pharmaceuticals's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Oramed Pharmaceuticals's Cyclically Adjusted PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Oramed Pharmaceuticals's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Oramed Pharmaceuticals's Cyclically Adjusted PB Ratio falls into.



Oramed Pharmaceuticals Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Oramed Pharmaceuticals's Cyclically Adjusted PB Ratio for today is calculated as

Cyclically Adjusted PB Ratio=Share Price/ Cyclically Adjusted Book per Share
=8.457/9.83
=0.86

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Oramed Pharmaceuticals's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2024 is calculated as:

For example, Oramed Pharmaceuticals's adjusted Book Value per Share data for the three months ended in Mar. 2024 was:

Adj_Book=Book Value per Share/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=15.046/131.7762*131.7762
=15.046

Current CPI (Mar. 2024) = 131.7762.

Oramed Pharmaceuticals Quarterly Data

Book Value per Share CPI Adj_Book
201405 8.074 100.373 10.600
201408 7.530 100.352 9.888
201411 8.018 99.635 10.605
201502 7.553 99.032 10.050
201505 7.200 100.333 9.456
201508 7.856 100.548 10.296
201511 7.108 100.135 9.354
201602 9.127 100.040 12.022
201605 8.633 101.355 11.224
201608 7.268 101.617 9.425
201611 6.614 101.829 8.559
201702 5.869 102.779 7.525
201705 5.441 103.256 6.944
201708 5.149 103.587 6.550
201711 5.815 104.072 7.363
201802 5.201 105.052 6.524
201805 4.212 106.148 5.229
201808 6.553 106.383 8.117
201811 6.075 106.338 7.528
201902 5.336 106.649 6.593
201905 4.537 108.048 5.533
201908 4.082 108.245 4.969
201911 3.608 108.519 4.381
202002 2.549 109.139 3.078
202005 5.362 108.175 6.532
202008 5.081 109.662 6.106
202011 4.335 109.793 5.203
202102 6.394 110.968 7.593
202105 8.165 113.576 9.473
202108 12.001 115.421 13.702
202111 16.345 117.269 18.367
202203 15.402 121.301 16.732
202206 14.581 125.017 15.369
202209 14.387 125.227 15.139
202212 14.038 125.222 14.773
202303 13.819 127.348 14.300
202306 13.785 128.729 14.111
202309 13.545 129.860 13.745
202312 14.858 129.419 15.129
202403 15.046 131.776 15.046

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Oramed Pharmaceuticals  (XTAE:ORMP) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Oramed Pharmaceuticals Cyclically Adjusted PB Ratio Related Terms

Thank you for viewing the detailed overview of Oramed Pharmaceuticals's Cyclically Adjusted PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Oramed Pharmaceuticals (XTAE:ORMP) Business Description

Comparable Companies
Traded in Other Exchanges
Address
1185 Avenue of the Americas, Third Floor, New York, NY, USA, 10036
Oramed Pharmaceuticals Inc is a pharmaceutical company which is engaged in the research and development of pharmaceutical solutions, including an oral insulin capsule to be used for the treatment of individuals with diabetes, and the use of orally ingestible capsules or pills for delivery of other polypeptides. The ORMD-0801 is a proprietary product which is an orally ingestible insulin capsule for the treatment of diabetes. Its other product includes Oral Glucagon-like peptide-1 which is an incretin hormone, a type of gastrointestinal hormone that stimulates the secretion of insulin from the pancreas.